iSpecimen Inc. (NASDAQ:ISPC) Sees Significant Increase in Short Interest

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 112,840 shares, an increase of 119.2% from the April 30th total of 51,489 shares. Currently, 8.9% of the company’s stock are sold short. Based on an average daily trading volume, of 1,080,390 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research note on Tuesday, April 21st. Wall Street Zen raised shares of iSpecimen to a “sell” rating in a report on Saturday, May 2nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, iSpecimen presently has a consensus rating of “Sell”.

iSpecimen Stock Performance

NASDAQ:ISPC traded up $0.18 during trading hours on Monday, reaching $3.34. The company’s stock had a trading volume of 82,620 shares, compared to its average volume of 613,828. The firm has a market capitalization of $4.81 million, a price-to-earnings ratio of -0.05 and a beta of 1.62. The firm has a 50-day simple moving average of $5.10 and a 200-day simple moving average of $11.21. iSpecimen has a 1 year low of $3.10 and a 1 year high of $127.20.

iSpecimen (NASDAQ:ISPC) last issued its earnings results on Friday, May 15th. The company reported ($6.66) EPS for the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.The business had revenue of $0.16 million during the quarter.

Hedge Funds Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen at the end of the most recent reporting period. 13.62% of the stock is currently owned by hedge funds and other institutional investors.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.